In-depth guides, research summaries, and educational content for the scientific community.
Prostamax has two published studies naming it, both in human lymphocytes and both aimed at chromatin rather than prostate tissue. What they report, and what the prostate label rests on.
Cardiogen has two published studies naming it — one in myocardial tissue culture from young and old rats, one reporting a tumour-modifying effect in senescent rats. Both are ageing-model designs.
Bronchogen has one published study naming it — a biophysical measurement of its effect on DNA thermostability, which tests the family mechanism at the level of the molecule itself.
Testagen has exactly one study naming it in PubMed — and it is a materials-science paper on copper corrosion inhibition, not biology. What that means for anyone evaluating the compound.
Vesugen is the KED tripeptide that three other catalog compounds extend by a single residue — and it has no published study naming it. What is established, and the contrast with Pancragen.
Vesilut is the dipeptide Glu-Asp (ED) — a sequence contained within Prostamax, Vesugen, Livagen and Pancragen. Shared substructure is a hypothesis to test, not evidence to cite.
Epithalon is the one Khavinson bioregulator with current international replication. A citation-by-citation summary of the telomerase work, from the 2003 original through independent 2025 studies — including the correction notice.
Pinealon is the CNS-associated member of the Khavinson family, with published work on cell viability, free-radical suppression and prenatal hyperhomocysteinemia — all animal or cell models. What each study actually reports.
Cortagen is a cortex-derived tetrapeptide with published work on injured nerve function and cerebral ischaemia — plus a microarray study of its effect on gene expression in heart, which complicates the tissue-specificity story.
Livagen is one of the few bioregulators whose published work tests the family mechanism directly — chromatin activation in lymphocytes from older donors, using human cells rather than a phenotype proxy.
Pancragen has six published papers naming it — the largest compound-specific literature in the Khavinson family — including two studies in old rhesus monkeys. What primate data does and does not buy you.
Chonluten is a Thr-Glu-Asp tripeptide with no published study naming it. This page sets out what is verifiable, documents a molecular formula correction made to our own catalog, and is explicit about where the evidence stops.
